Encapsulation of anti-tuberculosis drugs within mesoporous silica and intracellular antibacterial activities

Xin Xia, Kevin Pethe, Ryangyeo Kim, Lluis Ballell, David Barros, Jonathan Cechetto, HeeKyoung Jeon, Kideok Kim, Alfonso E. Garcia-Bennett*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

19 Citations (Scopus)
84 Downloads (Pure)


Tuberculosis is a major problem in public health. While new effective treatments to combat the disease are currently under development, they tend suffer from poor solubility often resulting in low and/or inconsistent oral bioavailability. Mesoporous materials are here investigated in an in vitro intracellular assay, for the effective delivery of compound PA-824; a poorly soluble bactericidal agent being developed against Tuberculosis (TB). Mesoporous materials enhance the solubility of PA-824; however, this is not translated into a higher antibacterial activity in TB-infected macrophages after 5 days of incubation, where similar values are obtained. The lack of improved activity may be due to insufficient release of the drug from the mesopores in the context of the cellular environment. However, these results show promising data for the use of mesoporous particles in the context of oral delivery with expected improvements in bioavailability.

Original languageEnglish
Pages (from-to)813-826
Number of pages14
Issue number3
Publication statusPublished - Sept 2014
Externally publishedYes

Bibliographical note

Copyright the Author(s) 2014. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.


  • tuberculosis
  • mesoporous materials
  • solubility
  • intracellular
  • formulation
  • nanomedicine


Dive into the research topics of 'Encapsulation of anti-tuberculosis drugs within mesoporous silica and intracellular antibacterial activities'. Together they form a unique fingerprint.

Cite this